Collaboration with Dr Peter Gasser, Dr Thorsten Passie and MAPS

In 2008, we co-sponsored this MAPS-led trial of LSD-assisted psychotherapy for end-of-life anxiety. This was the first LSD study approved by the U.S. Food and Drug Administration in 40 years, and the results demonstrated that LSD paired with psychotherapy could alleviate ‘existential stress’ associated with terminal illness, putting the drug’s medical potential back in the spotlight for the first time since the 1960s.


Media Coverage

Read more about this study  in the New York Times, Huffington Post, Independent and Huffington Post blog

Our published studies

LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects

Journal of Psychopharmacology, 2015

Read more

Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases

The Journal of Nervous and Mental Disease, 2014

Read more